Lifeboat Foundation

A group of photonics researchers at Tampere University have introduced a novel method to control a light beam with another beam through a unique plasmonic metasurface in a linear medium at ultra-low power. This simple linear switching method makes nanophotonic devices such as optical computing and communication systems more sustainable, requiring low intensity of light.

A group of photonics researchers at Tampere University have introduced a novel method to control a light beam with another beam through a unique plasmonic metasurface in a linear medium at ultra-low power. This simple linear switching method makes nanophotonic devices such as optical computing and communication systems more sustainable, requiring low intensity of light.

All–optical switching is the modulation of signal light due to control light in such a way that it possesses the on/off conversion function. In general, a light beam can be modulated with another intense laser beam in the presence of a nonlinear medium.

The switching method developed by the researchers is fundamentally based on the quantum optical phenomenon known as Enhancement of Index of Refraction (EIR).

A study of the Type 2 diabetes drug tirzepatide found it resulted in dramatic weight loss, offering hope for those struggling with obesity.

Elon Musk accused Twitter of “resisting and thwarting” his right to information about fake accounts on the platform, calling it in a letter to the company on Monday a “clear material breach” of the terms of their merger agreement.

“Mr. Musk reserves all rights resulting therefrom, including his right not to consummate the transaction and his right to terminate the merger agreement,” the letter, signed by Skadden Arps attorney Mike Ringler, says.

Twitter shares were down 5% on Monday morning.

A drug combination targeting multiple mutant versions of cancer’s “death star” protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.

The two–drug combination was effective against advanced cancers with a range of mutations to the KRAS gene—dubbed the “death star” because its protein drives one in four cancers and has a largely impenetrable, drug-resistant surface.

The phase I trial tested the drugs VS-6766 and everolimus in 30 patients with a range of mutations to KRAS—including 11 with highly advanced, non-small cell lung cancer.

Circa 2016

Computer programs often contain defects, or bugs, that need to be found and repaired. This manual “debugging” usually requires valuable time and resources. To help developers debug more efficiently, automated debugging solutions have been proposed. One approach goes through information available in bug reports. Another goes through information collected by running a set of test cases. Until now, explains David Lo from Singapore Management University’s (SMU) School of Information Systems, there has been a “missing link” that prevents these information gathering threads from being combined.

Dr Lo, together with colleagues from SMU, has developed an automated debugging approach called Adaptive Multimodal Bug Localisation (AML). AML gleans debugging hints from both bug reports and test cases, and then performs a statistical analysis to pinpoint program elements that are likely to contain bugs.

Continue reading “Automatic debugging of software” »

Although the researchers cannot say for sure whether this was a direct result of tecovirimattreatment, the results suggest tecovirimat could help to prevent progression to severe disease and shorten the time spent in hospital. They recommend a 2-week course of treatment in order to fully clear the virus.

Speaking to Medical News Today, Dr. Stephen Morse, professor of epidemiology at the Columbia University Medical Center, and director of the Infectious Disease Epidemiology Certificate Program, noted that “tecovirimat is the most effective known antiviral for the orthopoxviruses, which includes smallpox — now officially eradicated — monkeypox, and others.”

“The mechanism of action of the drug, and the relatedness of these viruses, suggests that tecovirimat should be equally effective for other orthopoxviruses, but rigorous comparisons have not been possible because of small case numbers,” he added.